These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27692522)

  • 1. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.
    Melero JA; Mas V; McLellan JS
    Vaccine; 2017 Jan; 35(3):461-468. PubMed ID: 27692522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.
    Meshram CD; Baviskar PS; Ognibene CM; Oomens AGP
    J Virol; 2016 Dec; 90(23):10612-10628. PubMed ID: 27654298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.
    Melero JA
    Expert Rev Vaccines; 2016 Oct; 15(10):1319-25. PubMed ID: 27055009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution.
    Krueger S; Curtis JE; Scott DR; Grishaev A; Glenn G; Smith G; Ellingsworth L; Borisov O; Maynard EL
    Mol Pharm; 2021 Jan; 18(1):359-376. PubMed ID: 33322901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and function of respiratory syncytial virus surface glycoproteins.
    McLellan JS; Ray WC; Peeples ME
    Curr Top Microbiol Immunol; 2013; 372():83-104. PubMed ID: 24362685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G.
    Sugawara M; Czaplicki J; Ferrage J; Haeuw JF; Power UF; Corvaïa N; Nguyen T; Beck A; Milton A
    J Pept Res; 2002 Nov; 60(5):271-82. PubMed ID: 12383117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. trans-Complementation allows recovery of human respiratory syncytial viruses that are infectious but deficient in cell-to-cell transmission.
    Oomens AG; Wertz GW
    J Virol; 2004 Sep; 78(17):9064-72. PubMed ID: 15308702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification of human respiratory syncytial virus fusion glycoprotein.
    Zheng Y; Tang Y; Fu Y; He J; Wang X; Hong T
    Protein Expr Purif; 2012 Jan; 81(1):115-118. PubMed ID: 21979254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.
    Hause AM; Henke DM; Avadhanula V; Shaw CA; Tapia LI; Piedra PA
    PLoS One; 2017; 12(4):e0175792. PubMed ID: 28414749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative conformations of a major antigenic site on RSV F.
    Jones HG; Battles MB; Lin CC; Bianchi S; Corti D; McLellan JS
    PLoS Pathog; 2019 Jul; 15(7):e1007944. PubMed ID: 31306469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
    Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic structure of human respiratory syncytial virus fusion glycoprotein.
    López JA; Bustos R; Orvell C; Berois M; Arbiza J; García-Barreno B; Melero JA
    J Virol; 1998 Aug; 72(8):6922-8. PubMed ID: 9658147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the binding of monoclonal and polyclonal antibodies to the glycoproteins of antigenic variants of human respiratory syncytial virus by surface plasmon resonance.
    McGill A; Marsh R; Craft AW; Toms GL
    J Immunol Methods; 2005 Feb; 297(1-2):143-52. PubMed ID: 15777938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17.
    Bin Lu ; Liu H; Tabor DE; Tovchigrechko A; Qi Y; Ruzin A; Esser MT; Jin H
    Sci Rep; 2019 Mar; 9(1):3898. PubMed ID: 30846850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 20. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.